Classification and Mechanism of Action
Ranitidine is classified as an antisecretory agent — a medication that inhibits hydrochloric acid secretion in the stomach. Pharmacologically, it is a second-generation $H_2$-histamine receptor blocker.
Mechanism of Action: The drug acts as a competitive antagonist of histamine. Its target site is the $H_2$ receptors located directly on the membrane of the gastric parietal cell. By blocking these receptors, the drug interrupts the stimulating signal from histamine, leading to a decrease in hydrochloric acid production.
Target Differential Diagnosis: To understand the gastrointestinal pharmacological map, it is important to distinguish ranitidine's mechanism from other antisecretory drug classes:
- Proton Pump Inhibitors (PPIs) (e.g., omeprazole) — block $H^+/K^+$-ATPase. This is the most potent mechanism because it shuts down the final step of acid secretion.
- Antimuscarinics (M-cholinergic blockers) — act on different receptors: pirenzepine blocks $M_1$ receptors (at the level of ganglia and ECL cells), while atropine blocks $M_3$ receptors (on parietal cells).
- Gastrin receptor antagonists (proglumide) — block gastrin receptors.
- Prostaglandin analogues (misoprostol) — stimulate PG receptors, suppressing cAMP synthesis.
Pharmacological Features and Advantages
As a second-generation drug, ranitidine has several clinically significant differences from its predecessor, cimetidine (1st generation):
- High Efficacy: Acts as a more potent antisecretory agent.
- Duration of Action: The effect persists for a long time (10 to 12 hours), allowing for a convenient dosing regimen of just twice daily.
- No Effect on Other Drugs' Metabolism: This is a key safety profile advantage. Unlike cimetidine (which is a known inhibitor), ranitidine does not inhibit microsomal oxidation in the liver. It does not affect cytochrome P450 isoenzymes (including CYP2D6), so it can be safely combined with psychotropic drugs (haloperidol, tricyclic antidepressants), antiarrhythmics, and opioids (codeine) without fear of delayed elimination.
Side Effects
The drug has a favorable safety profile and rarely causes adverse effects. In rare cases, the following may occur:
- Headache.
- Gastrointestinal tract: constipation.
Formulations and Prescriptions
The drug (Ranitidin) is available for both enteral and parenteral administration:
- Tablets: 0.15 g and 0.3 g. Standard oral dosage is 0.15 g twice daily.
- Solution for Injection: 2.5% in 2 mL ampoules. Administered intravenously or intramuscularly at a dose of 0.05 g (corresponding to 2 mL of a 2.5% solution).
Sample Tablet Prescription: ```latin Rp.: Tab. Ranitidini 0.15 D.t.d. N. 20 S. Take 1 tablet orally twice daily. ```
Sample Ampoule Prescription: ```latin Rp.: Sol. Ranitidini 2.5% - 2 ml D.t.d. N. 10 in amp. S. Administer 2 mL (0.05 g) intramuscularly once daily. ```